# EMD Serono clinical trials: 91 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 91 trials with EMD Serono as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by EMD Serono: 91 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/emd-serono

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 91
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 91, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 17, 2014 | NCT02117050 | RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate | EMD Serono | Phase 4 | Terminated | Multiple Sclerosis | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02117050) |
| March 11, 2014 | NCT02083679 | Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer | EMD Serono | Phase 1 | Terminated | Carcinoma, Non-Small-Cell Lung | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02083679) |
| February 25, 2014 | NCT02070978 | Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) | EMD Serono | Phase 2 | Terminated | Lupus Erythematosus, Systemic | 253 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02070978) |
| January 30, 2014 | NCT02049151 | Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer | EMD Serono | Phase 3 | Terminated | Carcinoma, Non-Small-Cell Lung | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02049151) |
| December 24, 2013 | NCT02019550 | Rebif® Rebidose® Versus Rebiject II® Ease-of-Use | EMD Serono | Phase 4 | Completed | Multiple Sclerosis, Relapsing-Remitting | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02019550) |
| November 25, 2013 | NCT01992874 | Relative Bioavailability of Pimasertib in Cancer Patients | EMD Serono | Phase 1 | Completed | Neoplasms | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01992874) |
| October 31, 2013 | NCT01973608 | MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma | EMD Serono | Phase 2 | Terminated | Melanoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01973608) |
| October 30, 2013 | NCT01972568 | Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus | EMD Serono | Phase 2 | Completed | Lupus Erythematosus, Systemic | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01972568) |
| October 29, 2013 | NCT01971515 | First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies | EMD Serono | Phase 1 | Completed | Solid Tumor | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01971515) |
| October 16, 2013 | NCT01963611 | Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) | EMD Serono | Phase 2 | Terminated | Relapsing Remitting Multiple Sclerosis | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01963611) |
| September 6, 2013 | NCT01936363 | Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer | EMD Serono | Phase 2 | Completed | Ovarian Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01936363) |
| July 23, 2013 | NCT01905527 | Adherence Trial With MS LifeLines ® Services | EMD Serono | Observational | Terminated | Multiple Sclerosis, Relapsing-Remitting | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01905527) |
| September 26, 2012 | NCT01693068 | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | EMD Serono | Phase 2 | Completed | N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01693068) |
| September 21, 2012 | NCT01689337 | A Multicenter Trial of Sprifermin (AS902330 \[Recombinant Human Fibroblast Growth Factor-18\]) or Placebo After Microfracture Surgery for... | EMD Serono | Phase 2 | Terminated | Cartilage Injury of Knee | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01689337) |
| December 21, 2011 | NCT01496131 | Tecemotide (L-BLP25) in Prostate Cancer | EMD Serono | Phase 2 | Completed | Prostate Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01496131) |
| October 17, 2011 | NCT01453387 | MSC2015103B in Solid Tumors | EMD Serono | Phase 1 | Terminated | Advanced Solid Tumor | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01453387) |
| September 26, 2011 | NCT01440231 | Atacicept Demonstrating Dose RESponSe | EMD Serono | Phase 2 | Withdrawn | Systemic Lupus Erythematosus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01440231) |
| July 11, 2011 | NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | EMD Serono | Phase 1 | Completed | Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Melanoma, Colorectal... | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01390818) |
| June 22, 2011 | NCT01378377 | Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus | EMD Serono | Phase 1 | Terminated | Advanced Solid Tumor | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01378377) |
| June 9, 2011 | NCT01369628 | Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil | EMD Serono | Phase 1 | Terminated | Lupus Nephritis | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01369628) |
| May 26, 2011 | NCT01360840 | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer | EMD Serono | Phase 2 | Completed | Prostate Cancer Metastatic | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01360840) |
| November 9, 2010 | NCT01237340 | Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study | EMD Serono | Phase 3 | Terminated | Growth Hormone Deficiency (GHD) | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01237340) |
| October 22, 2010 | NCT01226745 | Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) | EMD Serono | Phase 2 | Terminated | Multiple Sclerosis | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01226745) |
| September 23, 2010 | NCT01207648 | Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) | EMD Serono | Observational | Completed | Multiple Sclerosis | 307 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01207648) |
| June 29, 2010 | NCT01152866 | An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART) | EMD Serono | Observational | Completed | Ovulation Induction, Infertility | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01152866) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 1/2 | 2 |
| Phase 2 | 27 |
| Phase 2/3 | 4 |
| Phase 3 | 24 |
| Phase 4 | 9 |
| Observational | 8 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 62 |
| Terminated | 26 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Sclerosis | 14 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Multiple Sclerosis, Relapsing-Remitting | 8 |
| Neoplasm Metastasis | 4 |
| Colorectal Neoplasms | 4 |
| Infertility | 4 |
| Ovarian Neoplasms | 4 |
| Neoplasms | 4 |
| Dwarfism, Pituitary | 4 |
| Lupus Erythematosus, Systemic | 4 |
| Parkinson Disease | 3 |
| Dyskinesias | 3 |
| Breast Neoplasms | 3 |
| Melanoma | 3 |
| Glioblastoma | 3 |
| Recurrence | 3 |
| Helping Behavior | 2 |
| HIV Infections | 2 |
| Lupus Nephritis | 2 |
| Lung Neoplasms | 2 |
| Prostatic Neoplasms | 2 |
| Arthritis, Rheumatoid | 2 |
| Brain Neoplasms | 1 |
| Lipodystrophy | 1 |
| Optic Neuritis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cooking schools in the United States](https://specstream.ai/data/businesses/cooking-schools/united-states)
- [Bakeries in the United States](https://specstream.ai/data/businesses/bakeries/united-states)
- [Web hosting companies in the United States](https://specstream.ai/data/businesses/web-hosting-companies/united-states)
- [Social media agencies in the United States](https://specstream.ai/data/businesses/social-media-agencies/united-states)
- [Personal injury law firms in the United States](https://specstream.ai/data/businesses/personal-injury-law-firms/united-states)
- [Locksmiths in the United States](https://specstream.ai/data/businesses/locksmiths/united-states)
